Should We Use Left Atrial Appendage Occlusion More Frequently? What Real-Life Data Are Available?

Left atrial appendage occlusion (LAAO) is an alternative to prevent atrial fibrillation stroke mainly used in patients at high risk for bleeding.

¿Debemos utilizar con mayor frecuencia el cierre de orejuela de la aurícula izquierda? ¿Qué datos tenemos de la vida real?

One of the most widely used devices in randomized trials is the Watchman, which yielded promising results. However, its real-life performance had yet to be analyzed.

Researchers conducted an analysis of the National Cardiovascular Data Registry of the American College of Cardiology, which includes 366,814 patients implanted with the Watchman device.

The primary endpoint (PEP) was ischemic stroke, while the secondary endpoint (SEP) included death, hemorrhagic stroke, undetermined stroke, intracranial bleeding, any stroke, systemic embolism, and major bleeding.

Mean age was 76 years old, 58% of the patients were male, patient BMI was 30 [sic], over 90% of patients were hypertensive, 38% had diabetes, 25% had a prior stroke, 14% had a prior TIA, and 18% had a history of thromboembolism.

The HAS-BLED score was 3 and the CHA2DS2-VASc score was 4.8; 70% of patients experienced major bleeding, 42% experienced digestive bleeding, and 12% experienced intracranial bleeding.

Read also: WOEST 2 | Dual Versus Triple Antithrombotic Scheme in the Real World. Antiplatelet Therapy. Anticoagulation Scheme.

Atrial fibrillation was paroxysmal in 52% of cases; in all others, it was permanent or persistent.

Procedural success was 97%.

At discharge, 50% of patients received aspirin plus anticoagulation (warfarin or DOAC) and, to a lesser extent, anticoagulation or dual antiplatelet therapy.

Read also: Ticagrelor Shows Benefits in Coronary Microvascular Function after NSTEMI.

A one-year follow-up was conducted for 93.6% of patients.

The PEP was 1.53% (95% confidence interval: 1.39%-1.69%), the ischemic stroke rate was 2.19%, and all-cause mortality was 8.5%. The composite of stroke, systemic embolism, or death at a year was 10.7%. Major bleeding was 6.9% (mostly occurring within 45 days after discharge).

Conclusion

This study highlights the importance of the evolution of a cohort in the US with percutaneous closure of the left atrial appendage. Knowing the data, physicians and patients can make joint decisions on this therapy.

Dr. Carlos Fava - Consejo Editorial SOLACI

Dr. Carlos Fava.
Member of the editorial board of SOLACI.org .

Original Title: Clinical Outcomes at 1 Year Following Transcatheter Left Atrial Appendage Occlusion in the United States.

Reference: Matthew J. Price, et al. J Am Coll Cardiol Intv 2022;15:741–750.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

More articles by this author

TCT 2024 | TRISCEND II

This randomized study included 400 patients; 267 were treated with EVOQUE valve and 133 with optimal medical treatment (OMT). After one-year follow-up, there were no...

TCT 2024 – ACCESS-TAVI: Comparing Percutaneous Access Closure Strategies After TAVI

Vascular access complications following transcatheter aortic valve implantation (TAVI) remain common. However, few studies compare vascular access closure methods.  Based on the CHOICE-CLOSURE and MASH...

TAVR in Young Low-Risk Patients

Transcatheter aortic valve replacement (TAVR) has established itself as an effective strategy for the treatment of severe aortic stenosis across different risk groups. While previous...

TAVR and Atrial Fibrillation: What Anticoagulants Should We Use?

The prevalence of atrial fibrillation (AF) in TAVR patients ranges from 15 to 30%, depending on series. This arrhythmia has been associated to higher...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

TCT 2024 | FAVOR III EUROPA

The study FAVOR III EUROPA, a randomized trial, included 2,000 patients with chronic coronary syndrome, or stabilized acute coronary syndrome, and intermediate lesions. 1,008...

TCT 2024 | TRISCEND II

This randomized study included 400 patients; 267 were treated with EVOQUE valve and 133 with optimal medical treatment (OMT). After one-year follow-up, there were no...

TCT 2024 – ACCESS-TAVI: Comparing Percutaneous Access Closure Strategies After TAVI

Vascular access complications following transcatheter aortic valve implantation (TAVI) remain common. However, few studies compare vascular access closure methods.  Based on the CHOICE-CLOSURE and MASH...